분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2016-03-14 13:54:53 , Hit : 698
 Tunable Form of CRISPR Is an Efficient Regulator of Stem Cell Expression


GEN News Highlights

Mar 11, 2016

Combining powerful technologies in biology can often have an exceptionally synergistic effect that leads to fundamental breakthroughs in how researchers look at normal metabolic pathways or aberrant disease states. This is what researchers from the Gladstone Institute hope will emerge from their recent use of a relatively new variation of the CRISPR-Cas9 system on the genome of induced pluripotent stem cells (iPSCs)—offering a significant technological advance in creating cell models of genetic diseases.    

In the newly published study, researchers used a modified version of CRISPR called CRISPR interference (CRISPRi) to inactivate genes in iPSCs and heart cells created from iPSCs. The method, first reported in 2013 by Stanley Qi, Ph.D., who is a co-author on the current paper, significantly improves the original CRISPR-Cas9 system by allowing genes to be silenced more precisely and efficiently. Additionally, CRISPRi also offers the flexibility of reversing and carefully controlling the amount of gene suppression.

The standard CRISPR system uses the Cas9 protein to delete a precise part of the genome through small cuts in a cell's DNA. CRISPRi builds on this technology by using a special deactivated version of the Cas9 protein along with an additional inhibitor protein, Krüppel-associated box, or KRAB. Together, these proteins sit at the target spot on the genome and suppress gene expression without excising the DNA.

“We developed clustered regularly interspaced short palindromic repeat interference (CRISPRi) to repress gene expression in human induced pluripotent stem cells (iPSCs),” the authors wrote. “CRISPRi, in which a doxycycline-inducible deactivated Cas9 is fused to a KRAB repression domain, can specifically and reversibly inhibit gene expression in iPSCs and iPSC-derived cardiac progenitors, cardiomyocytes, and T lymphocytes. This gene repression system is tunable and has the potential to silence single alleles.”

Surprisingly the investigators found that temporarily silencing gene expression in this manner was much more consistent than permanently cleaving the genome.

"We were amazed by the dramatic difference in performance between the two systems," remarked senior study author Bruce Conklin, M.D., senior investigator at the Gladstone Institute of Cardiovascular Disease and Roddenberry Stem Cell Center. "We thought that permanently cutting the genome would be the more effective way to silence a gene, but in fact, CRISPRi is so precise and binds so tightly to the genome that it is actually a better way to silence a gene."

In the current study, the Gladstone scientists compared how well CRISPRi and CRISPR-Cas9 silenced a particular gene that controls iPSC pluripotency. They discovered that CRISPRi was much more efficient than CRISPR-Cas9, because, in 95% of the cells created using CRISPRi, the target gene was silenced, compared to only 60–70% of cells grown from traditional CRISPR-Cas9 editing. Moreover, CRISPRi also did not cause any off-target changes in gene expression, like undesired insertions or deletions to the cell's genome, which is typically a cause for concern with CRISPR-Cas9.

The findings from this study were published recently in Cell Stem Cell in an article entitled “CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs.”

Another advantage of CRISPRi is that it can act as a toggle switch, enabling the scientists to reverse gene suppression by simply removing the chemical that turns on the gene inhibitor. In the current study, the researchers were able to tune how much they silenced a gene by changing the amount of the chemicals they added. Both of these results support much more versatile investigations into the role of individual genes that affect development and disease.

"CRISPRi holds a major advantage in making disease-relevant cell types," explained lead author Mohammad Mandegar, D.Phil., research scientist at Gladstone. "Using this technology, we can mimic disease in a homogeneous population of heart cells created from iPSCs. This development allows us to study genetic diseases more easily and potentially identify new therapeutic targets."







  Tunable Form of CRISPR Is an Efficient Regulator of Stem Cell Expression  이성욱 2016/03/14 698
1106   NIH 연구진들은 5가지 종류의 암에서 공유되는 충격적인 게놈 상의 특징을 확인  이성욱 2016/03/09 828
1105   특허전쟁: 미국 특허청, CRISPR의 특허권 중재 시작  이성욱 2016/03/08 1045
1104   거대 바이러스에게서도 발견된 CRISPR 유사 시스템  이성욱 2016/03/02 1122
1103   MIT 선정 2015년 주목받은 Biomedicine 뉴스  이성욱 2016/02/03 886
1102   CRISPR Editing of Human Embryos Approved in the U.K.  이성욱 2016/02/02 806
1101   CRISPR Fixes Stem Cells Harboring Blindness-Causing Defect  이성욱 2016/02/01 761
1100   유전자치료제 연구개발 및 규제 동향 2015-식품의약품안전처  이성욱 2016/01/20 1061
1099   융합연구리뷰 | Convergence Research Review  이성욱 2016/01/08 1054
1098   유전자 편집 기술로 작물 유전자 편집  이성욱 2015/12/05 1162
1097   장 펑, 좀 더 정확한 유전자가위 개발  이성욱 2015/12/05 915
1096   세계 20여 개국 과학자들, 유전자편집 정상회담 개최  이성욱 2015/12/05 1076
1095   유전자 편집이란 무엇인가? 누구나 알아야 할 7가지 사실  이성욱 2015/12/05 1126
1094   목숨을 위협하는 바이러스 감염에 대한 유망 치료법  이성욱 2015/11/26 1145
1093   C형 간염에 보다 효과적인 새로운 복합제  이성욱 2015/11/24 975
1092   유전자 드라이브의 안전성 업그레이드  이성욱 2015/11/19 1129
1091   인간에게 꼭 필요한 유전자는 3,230개  이성욱 2015/11/18 875
1090   유전자편집치료에 희망을 준 백혈병치료  이성욱 2015/11/11 1101
1089   [바이오토픽] C형간염을 3주 만에 치료하는 DAA 3제요법  이성욱 2015/11/02 1066
1088   미 FDA, 암 잡는 바이러스 승인  이성욱 2015/10/30 1136

[1][2][3][4][5][6][7][8] 9 [10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN